A study with Kohnan Hospital, Iwate Prefectural Central Hospital, and Tohoku University Hospital was published in Front Neurol.
Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study. Front Neurol 15:1413632, 2024.
Recent randomized phase 3 trial in Japan demonstrated that clazosentan reduces cerebral vasospasm and improved outcome after subarachnoid hemorrhage (SAH) compared with placebo. However, real-world data comparing clazosentan with conventional standard management such as intravenous fasudil chloride are still lacking.
In this study, we compared the efficacy and safety of clazosentan in a group treated with a postoperative management protocol based on clazosentan (n = 81) with a group managed with a conventional protocol (n = 100) after SAH. The results showed that a postoperative management protocol centering on clazosentan was associated with the reduced vasospasm-related symptomatic infarction and improved clinical outcomes compared to the conventional management protocol in Japanese clinical practice. Clazosentan might be a promising treatment option for counteracting cerebral vasospasm after aneurysmal SAH.
This study is a single-center (Konan Hospital) retrospective observational cohort study using data collected from consecutive cases of aneurysmal SAH.